Stemnovate Year 2024 Overview
The year 2024 has been a defining period for Stemnovate, marked by specific challenges as we reached out to patients worldwide, navigating various regulatory and language hurdles. However, it also brought new opportunities, including establishing partnerships globally.
Our commitment to addressing unmet medical needs has led us to initiate research into rare diseases, particularly those affecting children. Our goal is to develop innovative treatments, which hold great promise and can only be achieved using novel cell models to study brain, liver, and cardiac functions.
Liver Platform
Stemnovate has pioneered a unique technology for liver modelling, which represents a significant achievement in this field. This breakthrough is especially noteworthy given that liver cells, despite their ability to proliferate, have been notoriously difficult to cultivate in the lab, resulting in questionable data reproducibility. Traditional cell lines often fail to exhibit variable drug metabolism.
?
Our recent publication with Trinity College Dublin in Oxford Immunology highlights our expertise in liver modelling for complex diseases, facilitating studies on immunological responses.?
Nervous Platform
The nervous system, with its intricate structure and functions, presents one of the most complex challenges in medical research. Effective models must not only resemble neurons morphologically but also provide insights into electrophysiological and neurotransmitter interactions.
Recognising this complexity, Stemnovate received a campus collaboration grant with Professor Nick Ktistakis at Babraham to develop a model for studying autophagy in Alzheimer’s disease. This proof-of-concept study has subsequently led to the establishment of two PhD studentships at the Babraham Institute, where students work in Stemnovate's lab to advance scientific understanding and gain valuable experience in application development.
Rare Diseases in Children
Modelling rare diseases in children is particularly challenging due to complex disease pathology, ethical considerations, small patient cohorts, and often short life spans.
These factors necessitate innovative thinking and the integration of diverse expertise, stakeholders, and technologies to create valuable models for developing new treatments.
Stemnovate is collaborating with leading pharmaceutical companies to develop innovative treatments for mitochondrial rare diseases. Our children’s platform, which has received essential NHS-HRA ethical approval, exemplifies our commitment to ethical research and has received positive feedback from parents, charities, and clinicians in this field.
Animal Health Platform
Our unwavering commitment to reducing animal testing led us to commercially deliver models for animal health companies, replacing animal studies with cell models last year. We are not only continuing this objective but have also brought to market the most advanced technologies that promote animal welfare, including multi-animal species karyotyping to identify any chromosomal or genomic changes that affect breeds and cause diseases. This technology holds great value for companies developing cell lines for cultured meat to ensure safety for end consumers.
Breed identification is another great tool for managing pets more effectively, and we are incredibly excited to introduce our innovative oral health technology. This technology, which reflects overall health, is designed to prevent zoonotic diseases, and enables veterinarians to make informed treatment decisions. This demonstrates our commitment to animal welfare and our innovative approach to animal health.
领英推荐
?
Moreover, we are dedicated to reducing our carbon footprint by introducing free shipping on our products in Cambridge, making them available through local stores and providing live cell cultures. This approach reduces the need for complex packaging and dry ice, representing a small step in the right direction.
Our data platform further supports this mission by allowing customers to benefit from our data and R&D expertise.
Events
World Orphan Drug Congress 2024 in Barcelona
We attended the World Orphan Drug Conference in Barcelona, where we established a network with partners working in the field of rare diseases.
?
Cambridge Scientists Network Meetup Group
We have been actively organizing Meetup events in Cambridge on various research topics, and our network has grown to over 120 members and continues to expand.
Products
We have introduced a new service, Oral health tests for animals.
Our at-home kit, a user-friendly solution, provides a comprehensive and accurate analysis of microbes. It uses advanced metagenomic techniques at Stemnovate Labs to assess your pet's oral and dental health, offering pet owners a valuable tool for proactive pet care.
The kit features a state-of-the-art data platform, sequencing, and bioinformatic analysis, which highly profiles the oral microbiome.
We are excited to announce that you can purchase our products online from our website.
?
Signing up is easy, MTAs are hassle-free, and we offer prompt shipping worldwide.